glp 1 insurance changes CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs Perspectives from employers on the

[DOI] [PubMed] [Google Scholar] 16.Nauck M.A., Meier J.J

It is not recommended for people who also take lixisenatide or other medicines called glucagonlike peptide 1 (GLP-1) receptor agonists

A clinician may lower a dose when side effects are getting in the way of normal life, then watch to see whether appetite control remains good enough

The review shows that exenatide seemed to decrease the heavy drinking days in obese people through its effect on the brain areas controlling drug reward and addiction (Klausen et al 37 )

Bahour N, Cortez B, Pan H, Shah H, Doria A, Aguayo-Mazzucato C (2022) Diabetes mellitus correlates with increased biological age as indicated by clinical biomarkers